E-viri
Recenzirano
Odprti dostop
-
Parfrey, Patrick S.
Kidney international, October 2018, 2018-10-00, 20181001, Letnik: 94, Številka: 4Journal Article
Use of calcimimetics will be influenced not only by assessment of benefits and harms in individual patients but also by cost and by national guidelines. The Japanese Society for Dialysis Therapy has a lower PTH threshold for PTH control than other countries. The current RCT, despite its limitations, provides a rationale for use of evocalcet in the management of secondary hyperPTH.
